Home/Filings/4/0001209191-21-048448
4//SEC Filing

Genexine Inc. 4

Accession 0001209191-21-048448

CIK 0001509261other

Filed

Jul 27, 8:00 PM ET

Accepted

Jul 28, 5:24 PM ET

Size

11.1 KB

Accession

0001209191-21-048448

Insider Transaction Report

Form 4
Period: 2019-04-26
Genexine Inc.
10% Owner
Transactions
  • Conversion

    Series AA Preferred Stock

    2019-04-26$10.00/sh1,250,000$12,500,0000 total
    Exercise: $0.22Common Stock (56,818,175 underlying)
  • Conversion

    Common Stock

    2019-04-26+56,818,17556,818,175 total
  • Purchase

    Common Stock

    2019-07-23$0.29/sh+34,482,758$10,000,00091,300,933 total
Footnotes (4)
  • [F1]Reporting Person acquired 1,250,000 shares of Issuer's Series AA Preferred Stock on January 30, 2019. Each share of the Issuer's Series AA Preferred Stock is convertible into shares of the Issuer's Common Stock at a ratio of 45.45454 shares of Common Stock for one share of Series AA Preferred Stock ("Conversion Rate") at the holder's election and has no expiration date. The Series AA Preferred Stock will automatically convert, at the Conversion Rate, into Common Stock (i) at any time upon the vote or consent of the holders of two thirds of the voting power of the then outstanding Series AA Preferred Stock or (ii) the amendment to Issuer's Certificate of Incorporation to increase the number of shares of Common Stock authorized to be issued to at least 500,000,000 shares of Common Stock.
  • [F2]Upon the filing of Issuer's amendment to Certificate of Incorporation on April 26, 2019, which amendment increased the authorized number of shares of Common Stock of the Issuer to 500,000,000, each share of Series AA Preferred Stock automatically converted into shares of the Issuer's Common Stock at the Conversion Rate.
  • [F3]Issuer granted Reporting Person a call option whereby the earlier of, (i) December 31, 2020 and (ii) the date when Issuer asks Reporting Person for further financing, Reporting Person may elect to purchase up to $10,000,000 worth of shares of the Issuer's Common Stock at a purchase price equal to the greater of: (i) $0.29 per share or (ii) 75% of the volume weighted average closing price of the Issuer's Common Stock during the thirty (30) consecutive trading days prior to the date of the notice. Pursuant to a Purchase Agreement for Shares of Common Stock dated July 23, 2019, Reporting Person exercised the full call option to purchase Common Stock.
  • [F4]Such amount now represents 1,826,019 shares of common stock after taking into account the 50:1 reverse stock split effected October 7, 2020.

Issuer

Rezolute, Inc.

CIK 0001509261

Entity typeother
IncorporatedKorea, Republic of

Related Parties

1
  • filerCIK 0001834377

Filing Metadata

Form type
4
Filed
Jul 27, 8:00 PM ET
Accepted
Jul 28, 5:24 PM ET
Size
11.1 KB